Pharma companies that want to make agile and patient-driven supply chains a reality need to look beyond their four walls and collaborate more closely with partners across the end-to-end supply chain, according to McKinsey & Company supply chain specialists Danny Kalmar and John Chartier. In this episode of our video podcast, Roddy Martin talks with Kalmar and Chartier about what it takes to make this transition while increasing supply chain resiliency and speeding up the “metabolic rate” of decision making.

Key Takeaways

• Over 80% of pharma company executives believe COVID-19 is prompting a fundamental shift toward making patient-driven supply chains a reality—and one of their top concerns is “the need for speed.”
• Analyzing demand from multiple points of view, rapidly identifying the implications of changes in patient demand, dynamic monitoring of demand forecasts, and advanced statistical forecasting are all becoming table stakes as pharma companies seek to build more agile, responsive, and resilient supply chains.
• Companies that invested in agile supply chain capabilities before the COVID-19 pandemic erupted have been better positioned to react, respond, and recover compared to companies that did not.